Avenzoar
Pharmaceuticals
Founded in 2016
Avenzoar Pharmaceuticals is a research-focused biotechnology company dedicated to the discovery and development of innovative cancer therapies.
These cancer drugs are aiming at targeting and inhibiting mechanisms of metastasis and drug resistance.
Founded on the principles of scientific excellence and patient-centric care, we strive to make a meaningful impact on the lives of cancer patients worldwide.
Key Accomplishments
Receiving orphan drug designation from the FDA for our pancreatic cancer treatment in July 2016 is a significant milestone for Avenzoar Pharmaceuticals. We anticipate a similar designation from the European Medicines Agency soon.
This status not only accelerates our approval process but also enhances our ability to bring this crucial treatment to cancer patients in need.






Our Strategy
To become a leader in oncology research and development by bringing novel, effective, and safe treatments to cancer patients in need. We focus on developing therapeutics that target multiple cancer-promoting pathways simultaneously. By doing so, we aim to treat recalcitrant cancers, particularly pancreatic and ovarian cancers, and target metastasis and chemo-resistance pathways.
To become a leader in oncology research and development by bringing novel, effective, and safe treatments to cancer patients in need. We focus on developing therapeutics that target multiple cancer-promoting pathways simultaneously. By doing so, we aim to treat recalcitrant cancers, particularly pancreatic and ovarian cancers, and target metastasis and chemo-resistance pathways.
Opportunities
We are seeking opportunities to bring our innovative therapies to market. Avenzoar’s deep expertise in cancer research and drug development with its threshold drug therapies in new small molecule therapeutics, including AP-001 are dedicated to advancing cancer treatment.
Board of Directors
At our core, we embody Innovation by pushing the boundaries of science to develop cutting-edge therapies, uphold Integrity by conducting research with the highest ethical standards, foster collaboration by partnering with industry leaders to advance cancer treatment, and maintain a steadfast Patient Focus by keeping cancer patients at the heart of everything we do.”
Shierley Widjaja - Board Member

Terrance Bruggeman
Executive Chairman of the Board of Directors
Stephen Thesing
Chief Executive Officer
Mouad Edderkaoui, PhD
Chief Scientific Officer
Stephen Pandol, MD
Chief Medical Officer
Shierley Widjaja
Shierley Widjaja has an impressive background in the biotech and pharmaceutical industries. She served as a Director at Prometheus Laboratories, Inc., and Prometheus Biosciences, Inc. Additionally, she worked as a Qualitative Research Associate at McKinley Capital Management. Shierley holds an undergraduate degree from the University of California, Los Angeles, and an MBA from The Wharton School of the University of Pennsylvania.